Exercise after heparin administration new: Therapeutic program for patients with non-option arteriosclerosis obliterans

Circulation Journal

Volumn 69, Issue 9, 2005, Pages 1099-1104

  Maejima, Yasuhiro ^a,b   Yasu, Takanori ^a   Ueba, Hiroto ^a   Kobayashi, Nobuhiko ^a   Hashimoto, Shigemasa ^a,c   Kubo, Norifumi ^a   Kakehashi, Akihiro ^a   Isobe, Mitsuaki ^b   Kawakami, Masanobu ^a   Saito, Muneyasu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c SAGA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Arteriosclerosis oblitrans; Exercise; Heparin; Hepatocyte growth factor

Indexed keywords

HEPARIN; SCATTER FACTOR;

ADULT; AGED; ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXERCISE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; OPHTHALMOSCOPY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL ACTIVITY; PHYSICAL CAPACITY; PROSPECTIVE STUDY; TREADMILL EXERCISE; VISUAL ACUITY; WALKING;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTERIOSCLEROSIS OBLITERANS; EXERCISE THERAPY; FEMALE; HEPARIN; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 27744569010     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.1099     Document Type: Article

References (34)

1. Second European Consensus Document on Chronic Leg Ischemia. Circulation 1991; 84(Suppl 4): IV-1-IV-26.
2. Schmieder FA, Comerota AJ. Intermittent claudication: Magnitude of the problem, patient evaluation, and therapeutic strategies. Am J Cardiol 2001; 87: 3D-13D.
3. Antonicelli R, Sardina M, Scotti A, Bonizzoni E, Parciaroni E. Randomized trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication: Italian CAP Study Group. Am J Med 1999; 107: 234-239.
4. Fujita M, Sasayama S, Asanoi H, Nakajima H, Sakai O, Ohno A. Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina. Circulation 1988; 77: 1022-1029.
5. Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem Biophys Res Commun 1999; 255: 80-87.
6. Salbach PB, Bruckmann M, Turoverts O, Kreuzer J, Kubler W, Walter-Sack I. Heparin-mediated selective release of hepatocyte growth factor in humans. Br J Clin Pharmacol 2000; 50: 221-226.
7. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-443.
8. Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J, et al. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral arterial disease. Hum Gene Ther 1996; 7: 959-988.
9. Aoki M, Morishita R, Taniyama Y, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by hepatocyte growth factor: Potential gene therapy for ischemic diseases. J Atheroscler Thromb 2000; 7: 71-76.
10. Wilkinson CP, Ferris FL III, Klein RE, Lee PP, Agardh CD, Davis M, et al; Representing the Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-1682.
11. Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis. Biochem Biophys Res Commun 1999; 255: 80-87.
12. Gowdak LH, Poliakova L, Wang X, Kovesdi I, Fishbein KW, Zacheo A, et al. Adenovirus-mediated VEGF121 gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 2000; 102: 565-571.
13. Matsumoto K, Nakamura T. Emerging multipotent aspects hepatocyte growth factor. J Biochem 1996; 119: 591-600.
14. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, et al. Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun 1995; 215: 483-488.
15. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: Additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens 1996; 14: 1067-1072.
16. Belle EV, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, et al. Potentiated angiographic effect of scatter factor/hepatocyte growth factor: The case for paracrine amplification of angiogenesis. Circulation 1998; 97: 381-390.
17. Rubin JS, Day RM, Breckenridge D, Atabey N, Tylor WG, Stahl SJ, et al. Dissociation of heparin sulfate and receptor binding domains of hepatocyte growth factor reveals that heparin sulfate-c-met interaction facilitates signaling. J Biol Chem 2001; 276: 32977-32983.
18. Yang R, Bunting S, Ko A, Schwall R, Jin H. Hemodynamic effects of scatter factor in conscious rats. J Cardiovasc Pharmacol 1997; 30: 294-301.
19. Sato T, Tani Y, Murao S, Fujieda H, Sato H, Matsumoto M, et al. Focal enhancement of expression of c-Met/hepatocyte growth factor receptor in the myocardium in human myocardial infarction. Cardiovasc Pathol 2001; 10: 235-240.
20. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997; 95: 2552-2558.
21. Yasuda S, Goto Y, Takaki H, Asaumi Y, Baba T, Miyazaki S, et al. Exercise-induced hepatocyte growth factor production in patients after acute myocardial infarction: Its relationship to exercise capacity and brain natriuretic peptide levels. Circ J 2004; 68: 304-307.
22. Gustafsson T, Knutsson A, Puntschart A, Kaijser L, Nordqvist AC, Sundberg CJ, et al. Increased expression of vascular endothelial growth factor in human skeletal muscle in response to short-term one-legged exercise training. Pflugers Arch 2002; 444: 752-759.
23. Lloyd PG, Prior BM, Yang HT, Terjung RL. Angiogenic growth factor expression in rat skeletal muscle in response to exercise training. Am J Physiol Heart Circ Physiol 2003; 284: H1668-H1678.
24. Maejima Y, Ueba H, Kuroki M, Yasu T, Hashimoto S, Nabata A, et al. Src family kinases and nitric oxide production are required for hepatocyte growth factor-stimulated endothelial cell growth. Atherosclerosis 2003; 167: 89-95.
25. Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998; 32: 1336-1344.
26. Scheffler P, de la Hamette D, Gross J, Mueller H, Schieffer H. Intensive vascular training in stage IIb of peripheral arterial occlusive disease: The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Circulation 1994; 90: 818-822.
27. Mehrabi MR, Serbecic N, Tamaddon F, Kaun C, Huber K, Pacher R, et al. Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. Cardiovasc Res 2002; 56: 214-224.
28. Ischemia Cronica degli Arti Inferiori Study Group. Prostanoids for chronic critical leg ischemia: A randomized, controlled, open-label trial with prostaglandin E1: The ICAI Study Group. Ann Intern Med 1999; 130: 412-421.
29. Mizushima Y, Yanagawa A, Hoshi K. Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for peripheral vascular diseases in man. J Pharm Pharmacol 1983; 35: 666 -667.
30. Yang R, Bunting S, Ko A, Schwall R, Jin H. Hemodynamic effects of scatter factor in conscious rats. J Cardiovasc Pharmacol 1997; 30: 294-301.
31. Xie X, Rivier AS, Zakrzewicz A, Bernimoulin M, Zeng XL, Wessel HP, et al. Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides: Studies with carboxyl-reduced and sulfated heparin and with trestatin a sulfate. J Biol Chem 2000; 275: 34818-34825.
32. Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Pique JM, et al. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000; 47: 88-96.
33. Hata N, Matsumori A, Yokoyama S, Ohba T, Shinada T, Yoshida H, et al. Hepatocyte growth factor and cardiovascular thrombosis in patients admitted to the intensive care unit. Circ J 2004; 68: 645-649.
34. Tateno S, Terai M, Niwa K, Jibiki T, Hamada H, Yasukawa K, et al. Alleviation of myocardial ischemia after Kawasaki Disease by heparin and exercise therapy. Circulation 2001; 103: 2591-2597.